WallStreetZenWallStreetZen

NASDAQ: AVTX
Avalo Therapeutics Inc Stock Ownership - Who owns Avalo Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Avalo Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jonathan GoldmanDirector2025-11-148,200$9.88
$81.02kBuy
Jonathan GoldmanDirector2025-11-143,167$14.30
$45.29kSell
Jonathan GoldmanDirector2025-11-148,200$14.35
$117.65kSell
Garry Arthur NeilChief Executive Officer2025-03-2817,787$8.46
$150.48kSell
Christopher Ryan SullivanChief Financial Officer2025-03-287,285$8.46
$61.63kSell

1 of 1

AVTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AVTX insiders and whales buy or sell their stock.

AVTX Shareholders

What type of owners hold Avalo Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Armistice Capital LLC284.63%51,615,185$1.03BInsider
Robert Moscato Jr.49.37%8,952,643$178.61MInsider
Randal Jones35.07%6,359,900$126.88MInsider
Steven Boyd12.94%2,345,714$46.80MInsider
Patrick J. Crutcher9.01%1,634,771$32.61MInsider
Bvf Inc7.47%1,355,256$27.04MInstitution
Orbimed Advisors LLC7.44%1,349,300$26.92MInstitution
Nantahala Capital Management LLC6.81%1,235,000$24.64MInstitution
Point72 Asset Management LP5.81%1,053,983$21.03MInstitution
Affinity Asset Advisors LLC5.55%1,006,217$20.07MInstitution

1 of 3

AVTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AVTX15.86%84.14%Net SellingNet Selling
NBY0.10%99.90%Net Buying
CADL41.26%31.10%Net Buying
MREO12.60%4.18%
ALLO67.48%32.52%Net SellingNet Selling
View Top Biotech Stocks

Avalo Therapeutics Stock Ownership FAQ

Who owns Avalo Therapeutics?

Avalo Therapeutics (NASDAQ: AVTX) is owned by 84.47% institutional shareholders, 448.05% Avalo Therapeutics insiders, and 0.00% retail investors. Armistice Capital LLC is the largest individual Avalo Therapeutics shareholder, owning 51.62M shares representing 284.63% of the company. Armistice Capital LLC's Avalo Therapeutics shares are currently valued at $1.01B.

If you're new to stock investing, here's how to buy Avalo Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.